Venetoclax combo holds promise for CLL

Preliminary results of a phase 2 trial of a three-drug protocol for chronic lymphocytic leukaemia (CLL) are “impressive”, leading to hopes that combinations including venetoclax may even cure some patients.

The German researchers hypothesised that venetoclax, which inhibits an apoptosis-regulating protein, might act synergistically with the human monoclonal antibody obinutuzumab in people with CLL.

But, in patients with a large volume of tumour cells, venetoclax has been associated with the potentially fatal tumour-lysis syndrome, so the